RALLYBIO CORPORATION Investing Cash Flow
RALLYBIO CORPORATION (RLYB) reported Investing Cash Flow of $23.40 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-26
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $5.50M, a 81.22% increase year-over-year.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $17.90M, a 61.54% increase year-over-year.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $3.92M.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $29.23M, a 31.62% increase year-over-year.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for fiscal 2023 was $27.66M.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for fiscal 2022 was -$112.17M.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for fiscal 2021 was -$2.33M.
- RALLYBIO CORPORATION net cash provided by (used in) investing activities for fiscal 2020 was -$2.07M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.50M derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $23.40M S-4/A · filed 2026-08-26 | $27.32M derived: sum of 3 quarters · filed 2026-08-26 | $56.55M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $17.90M S-4 · filed 2026-07-15 | $21.82M derived: sum of 2 quarters · filed 2026-08-26 | $51.05M derived: sum of 3 quarters · filed 2026-08-26 | $54.09M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $3.92M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $33.15M derived: sum of 2 quarters · filed 2026-08-26 | $36.19M derived: sum of 3 quarters · filed 2026-08-26 | $47.27M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $29.23M derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | $32.26M derived: sum of 2 quarters · filed 2026-08-26 | $43.34M 10-Q · filed 2025-11-06 | $41.77M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $3.04M derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $14.12M S-4/A · filed 2026-08-26 | $12.54M derived: sum of 3 quarters · filed 2026-08-26 | $34.75M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $11.08M S-4 · filed 2026-07-15 | $9.51M derived: sum of 2 quarters · filed 2026-08-26 | $31.71M derived: sum of 3 quarters · filed 2026-08-26 | $34.31M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$1.57M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $20.63M derived: sum of 2 quarters · filed 2026-08-26 | $23.23M derived: sum of 3 quarters · filed 2026-08-26 | $33.49M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $22.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $24.80M derived: sum of 2 quarters · filed 2025-11-06 | $35.06M 10-Q · filed 2025-11-06 | $51.97M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.86M 10-Q · filed 2025-08-07 | $29.77M derived: sum of 3 quarters · filed 2025-08-07 | $32.84M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $10.26M 10-Q · filed 2025-05-08 | $27.17M derived: sum of 2 quarters · filed 2025-05-08 | $30.24M derived: sum of 3 quarters · filed 2025-05-08 | $36.46M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $16.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $19.98M derived: sum of 2 quarters · filed 2025-03-13 | $26.19M derived: sum of 3 quarters · filed 2025-03-13 | $27.66M 10-K · filed 2025-03-13 |
| 2023-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $9.28M derived: sum of 2 quarters · filed 2024-11-07 | $10.75M 10-Q · filed 2024-11-07 | -$19.90M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $6.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.68M 10-Q · filed 2024-08-08 | -$22.97M derived: sum of 3 quarters · filed 2024-08-08 | -$17.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.47M 10-Q · filed 2024-05-09 | -$29.18M derived: sum of 2 quarters · filed 2024-05-09 | -$23.41M derived: sum of 3 quarters · filed 2024-05-09 | -$30.53M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$30.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$24.87M derived: sum of 2 quarters · filed 2024-03-12 | -$31.99M derived: sum of 3 quarters · filed 2024-03-12 | -$112.17M 10-K · filed 2024-03-12 |
| 2022-09-30 | $5.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.35M derived: sum of 2 quarters · filed 2023-11-09 | -$81.52M 10-Q · filed 2023-11-09 | -$81.66M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$7.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$87.30M 10-Q · filed 2023-08-08 | -$87.43M derived: sum of 3 quarters · filed 2023-08-08 | -$87.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$80.18M 10-Q · filed 2023-05-09 | -$80.31M derived: sum of 2 quarters · filed 2023-05-09 | -$80.44M derived: sum of 3 quarters · filed 2023-05-09 | -$81.95M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$267.00K derived: sum of 2 quarters · filed 2023-03-06 | -$1.77M derived: sum of 3 quarters · filed 2023-03-06 | -$2.33M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$1.63M derived: sum of 2 quarters · filed 2022-11-07 | -$2.20M 10-Q · filed 2022-11-07 | -$2.65M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$2.07M 10-Q · filed 2022-08-08 | -$2.52M derived: sum of 3 quarters · filed 2022-08-08 | -$2.54M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$562.00K 10-Q · filed 2022-05-10 | -$1.02M derived: sum of 2 quarters · filed 2022-05-10 | -$1.04M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$479.00K derived: sum of 2 quarters · filed 2022-03-15 | -$2.07M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.62M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$1.59M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |